Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
27 Février 2024 - 2:00PM
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded
with a mission to discover, develop and commercialize innovative,
first-in-class medicines that meet significant unmet medical needs,
today announced that Susan Rodriguez, chief commercial officer of
Ardelyx, will participate in a Cardiorenal panel discussion at the
Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
at 10:30 A.M. Eastern Time in Boston, MA.
To access the live webcast of the panel presentation please
visit the Events and Presentations page within the Ardelyx website
at https://ir.ardelyx.com/events-and-presentations. A replay of the
panel presentation will be available on the Ardelyx website for 30
days following the event.
About Ardelyx, Inc.Ardelyx was founded with a
mission to discover, develop and commercialize innovative,
first-in-class medicines that meet significant unmet medical needs.
Ardelyx has two commercial products approved in the United States,
IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as
early-stage pipeline candidates. Ardelyx has agreements for the
development and commercialization of tenapanor outside of the U.S.
Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for
hyperphosphatemia in Japan. A New Drug Application for tenapanor
for hyperphosphatemia has been submitted in China with Fosun
Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For
more information, please visit https://ardelyx.com/ and connect
with us on X (formerly known as Twitter), LinkedIn and
Facebook.
Investor and Media Contacts: Caitlin
Lowieclowie@ardelyx.com
Ardelyx (NASDAQ:ARDX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Ardelyx (NASDAQ:ARDX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024